For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.56 billion, representing a surprise of +5.15%. The company delivered an EPS surprise of +16.10%, with the consensus EPS estimate being $4.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharmaceuticals Incorporated UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________ ...

Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2024 adjusted earnings per share of $4.76, which beat the Zacks Consensus Estimate of $4.10. Earnings increased 56% year over year, driven by higher product revenues, lower costs and a lower tax rate in the quarter.The company reported total revenues of $2.69 billion, comprising cystic fibrosis (CF) product revenues. The figure beat the Zacks Consensus Estimate of $2.56 billion. Total revenues rose 13% year over year, primarily driven by high ...

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Susie Lisa - SVP, IR Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & COO Charles Wagner - EVP & CFO Conference Call Participants Geoff Meacham - Bank of America Merrill Lynch Jessica Fye - JPMorgan Chase & Co. Salveen Richter - Goldman Sachs Group Olivia Brayer - Cantor Fitzgerald & Co. Liisa Bayko - Evercore ISI Terence Flynn - Morgan Stanley Debjit Chattopadhyay - ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.10%. A quarter ago, it was expected that this drugmaker would post earnings of $4.10 per share when it actually produced earnings of $4.20, delivering a surprise of 2.44%.Over the last four quarters, the ...

Vertex Reports First Quarter 2024 Financial Results First Quarter 2024 Results Product revenue increased 13% to $2.69 billion compared to the first quarter of 2023, primarily driven in ex- U.S. markets by the continued strong uptake of TRIKAFTA /KAFTRIO , including label extensions in younger age groups, and in the U.S. by the continued performance of TRIKAFTA, including the uptake in children with CF 2 to 5 years of age. Net product revenue in the first quarter of 2024 increased 8% to $1.52 billion in the ...

Wall Street analysts expect Vertex Pharmaceuticals (VRTX) to post quarterly earnings of $4.10 per share in its upcoming report, which indicates a year-over-year increase of 34.4%. Revenues are expected to be $2.56 billion, up 7.8% from the year-ago quarter.The current level reflects an upward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Befor ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned -4.1% over the past month versus the Zacks S&P 500 composite's -4.1% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has lost 10.7% over this period. Now the key question is: Where could the stock be headed in t ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 6, 2024, might help the stock move higher if these key numbers are better ...

•  Vertex erhält eine exklusive Lizenz für TreeFrogs C-Stem™ Herstellungstechnologie bei Typ-1-Diabetes •  TreeFrog und Vertex arbeiten gemeinsam an der Weiterentwicklung von vollständig differenzierten, Insulin produzierenden Inselzellen der Bauchspeicheldrüse BOSTON und BORDEAUX, Frankreich, 24. April 2024 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) und TreeFrog Therapeutics gaben heute bekannt, dass Vertex eine exklusive Lizenz für TreeFrogs firmeneigene Zellherstellungstechnologie ...